Table 1 Comparison of those included and not included in the interaction cohort
Characteristic | Interaction cohort, n = 652 | Not in interaction cohort, n = 804 | Unadjusted p value |
|---|---|---|---|
Demographics | |||
 Sex (male), n (%) | 457 (70.1) | 600 (74.6) | 0.040 |
 Age (years), mean (SD) | 66.0 (11.5) | 64.4 (11.8) | 0.012 |
 BMI, median (IQR) | 28.3 (25.3–31.8) | 27.9 (24.9–31.4) | 0.21 |
Comorbidities | |||
 Smoking, n (%) | 185 (28.4) | 180 (22.4) | 0.011 |
 Cardiovascular multimorbidity | 218 (33.4) | 175 (21.8) | 6.1 × 10−7 |
 Non-cardiovascular multimorbidity | 167 (25.6) | 98 (12.2) | 4.1 × 10−11 |
 All multimorbidity | 385 (59.0) | 342 (42.5) | 3.7 × 10−10 |
 Number of comorbidities, n (%) | |||
  0 | 116 (17.8) | 205 (25.5) | 5.0 × 10−4 |
  1 | 151 (23.2) | 257 (32.0) | |
  2 | 152 (23.3) | 174 (21.6) | |
  3 | 107 (16.4) | 105 (13.1) | |
  4–5 | 117 (17.9) | 55 (6.8) | |
  6–7 | 9 (1.4) | 8 (1.0) | |
Index NSTE-ACS | |||
 Raised troponin, n (%) | 623 (95.6) | 765 (95.1) | 0.45 |
 Coronary catheterisation, n (%) | 445 (68.3) | 529 (65.8) | 0.32 |
 PCI/CABG, n (%) | 283 (43.4) | 376 (46.8) | 0.20 |
Cardiovascular drugs at discharge | |||
 Aspirin, n (%) | 612 (93.9) | 758 (94.3) | 0.52 |
 P2Y12 inhibitor, n (%) | 556 (85.3) | 680 (84.6) | 0.81 |
 ACEI/ARB, n (%) | 540 (82.8) | 651 (81.0) | 0.39 |
 Beta blocker, n (%) | 528 (81.0) | 664 (82.6) | 0.34 |
 Statin, n (%) | 609 (93.4) | 767 (95.4) | 0.026 |
 Number of patients on all five secondary prevention cardiovascular drugs, n (%)†| 373 (57.2) | 464 (57.7) | 0.84 |
 Number of cardiovascular drugs/patient, median (IQR, range)††| 6 (5–7, 0–9) | 6 (5–6, 2–10) | 0.11 |